We have placed cookies on your computer to help make this website better. We use a PIWIK Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by PIWIK (e.g. deny use/opt-out). More info.

Confirm

Fueling our pipeline with innovation

Our definition of innovation goes beyond simply drug development

Our R&D pipeline is a source of great excitement, indeed we currently have several new drug candidates and technologies in different phases of development, all of which are being actively managed to ensure a continuous flow of innovation with the potential to improve patient outcomes.

In our quest to improve the lives of even more patients in need, we enhance our expertise in pain management through complementary diversification into devices and technologies.

“Grünenthal is committed to deliver significant therapeutic advances to serve patients in need. In addition our highly valued collaborative spirit is building an enriched understanding of the underlying mechanisms driving pain that will allow us to discover and produce the medicines of the future.”

Paul Ratcliffe

Head of Research, Grünenthal


We recognise that our expertise, research capabilities and needs are different across pain, devices and technologies. In order to continuously strengthen our pipelines across our focus areas, we live an open and collaborative approach to R&D and in particular the blending of key elements:
  • driving our innovative projects via a broad networked approach
  • enriching our pipeline with external innovation projects and advancing these important collaborations
  • complementing our own capabilities with the extensive external knowledge and expertise to deliver real benefits.